To guarantee tumor-specific transgene expression, hypoxia-response elements (HREs) that serve as the binding site of HIFs localized in the promoter/enhancer regions of hypoxia-induced genes (for example: Epo, VEGF-A, PGK1) have been combined with tumor-specific promoters. Here, EPO is linked to neoplasm.